title: Thromboprophylaxis after multiple trauma: what treatment and for how long?
abstract: A review of current literature discussing thromboprophylaxis in the multiple-trauma patient to provide insight on the type of treatment and its duration of use. AMEDLINE search was conducted in May 2009 using keywords associated with thromboprophylactic measures in multiple-trauma patient care, including inferior vena cava (IVC) filters, mechanical-compression devices and anticoagulants. Abstracts were evaluated for relevance to this study and full-text articles were then examined individually. Fourteen full text articles were evaluated including guidelines published by the American College of Chest Physicians (ACCP) and the Eastern Association for the Surgery of Trauma (EAST) and other studies dealing with multiple-trauma patients, including those in hip-fracture surgery, lower-leg trauma and head trauma. Limited research has been performed for the multiple-trauma patient and recommendations regarding the type of treatment and its duration of use cannot be suggested beyond what has been extrapolated from existing trauma and major surgery patients. IVC filters, mechanical compression devices and anticoagulants therefore remain the standard, but their duration of use in the multiple-trauma patient is not well described. New oral anticoagulants that inhibit factor Xa or thrombin directly show promising qualities but have not been evaluated for multiple-trauma applications. Therefore, optimal thromboprophylaxis and its duration after multiple trauma is largely based on rational, clinical decision making on a case-by-case basis.
authors.affiliation: University of Louisville, Department of Orthopedic Surgery, Louisville, KY, USA.
authors.forename: Zachary C
authors.initials: ZC
authors.lastname: Yenna
authors.forename: Craig
authors.initials: C
authors.lastname: Roberts
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D020878:Device Removal; D065427:Factor Xa Inhibitors; D000077425:Fondaparinux; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D048228:Intermittent Pneumatic Compression Devices; D009025:Morpholines / Q000627:therapeutic use; D009104:Multiple Trauma / Q000150:complications / Q000188:drug therapy*; D011134:Polysaccharides / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D016306:Vena Cava Filters
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011134:Polysaccharides; D013876:Thiophenes; D006493:Heparin; D000069552:Rivaroxaban; D000077425:Fondaparinux